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their untreated female partners. Measures of efﬁcacy included
the Treatment Satisfaction Scale (TSS). The analysis was per-
formed in patients (partners) valid for intent-to-treat plus having
a baseline and post-baseline measurement, followed by subgroup
analysis regarding ED pre-treatment status. Separate analyses of
co-variance adjusting for baseline values and study effects were
conducted to investigate the change in treatment satisfaction in
patients and their partners using the TSS. RESULTS: At base-
line, TSS domain scores (least square means; LS means) were
similar for vardenaﬁl and placebo groups. Vardenaﬁl signiﬁ-
cantly (p < 0.0001) improved the treatment satisfaction for all
domains compared to placebo (LOCF; absolute difference in LS
means for patients and partners): ease of erection (23.4 and
24.9), erectile function satisfaction (36.7 and 32.9), pleasure
from sexual activity (23.0 and 23.7), satisfaction with orgasm
(27.6 and 21.8), conﬁdence to complete sexual activity (28.2 and
32.5), satisfaction with medication (37.4 and 35.6). The effect
of vardenaﬁl on treatment satisfaction in patients who had
received previous treatment with PDE5 inhibitors was even
higher for all domains (absolute difference in LS means between
vardenaﬁl and placebo groups for patients): ease of erection
(25.2), erectile function satisfaction (39.5), pleasure from sexual
activity (25.6), satisfaction with orgasm (29.8), conﬁdence to
complete sexual activity (30.4), satisfaction with medication
(41.3). CONCLUSIONS: Vardenaﬁl signiﬁcantly improved (p <
0.0001) treatment satisfaction in men with ED and their part-
ners. The treatment effect was even higher in patients who had
previously been treated with PDE5 inhibitors.
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OBJECTIVES: Data on prevalence, treatment, and stages of
COPD for Germany are limited. This study aims at investigat-
ing into prevalence and treatment of COPD as well as the 
distribution of COPD stages, frequency of comorbidity, and
exacerbations. METHODS: Claims data from a German sick-
ness fund were used to perform a retrospective cohort study. For
the period of 2001 to 2003 beneﬁciaries 45 years of age or older
were identiﬁed as COPD patients if they had a diagnosis of
emphysema and/or other chronic obstructive pulmonary diseases
(ICD-10 codes J43*, J44*) and/or at least one prescription for a
drug for obstructive airway diseases (ATC R03A*). Comorbid-
ity and exacerbations were identiﬁed according to related diag-
noses and prescriptions. Patients were allocated to COPD stages
by detection of drug prescription patterns as deﬁned by the
GOLD guideline (Pauwels et al., Am J Respir Crit Care Med
2001;163:1256–76). RESULTS: Among 499,550 beneﬁciaries
45 years of age or older 41,100 were identiﬁed as COPD patients
corresponding to a three-year prevalence rate of 8.2%, with rates
of 8.5% in men and 7.9% in women, respectively. Prevalence
rates of 9.3% in total, 9.6% in men, and 9.3% in women, respec-
tively, were estimated for the German resident population 45
years of age or older. For many of the COPD patients only few
speciﬁc drug prescriptions were detected within the three-year
observation period. Sixty-eight percent of patients were allocated
to GOLD stages 0 and 1 (at risk or mild COPD). Exacerbations
were found in 14,513 (35.4%), and comorbidity (mostly car-
diovascular disease) in 63% of patients. CONCLUSION: The
observed COPD prevalence rates are within the range of results
reported in former studies. The low level of treatment with
COPD-related drugs may be an indicator for a low awareness of
COPD among patients as well as among physicians.
PRS2
EFFECT OF DRG IMPLEMENTATION IN GERMANY—ANALYSIS
OF LENGTH OF HOSPITAL STAY OF IN-PATIENTS SUFFERING
FROM COMMUNITY-ACQUIRED PNEUMONIA
De Zeeuw J1, Pleiss C2, Ernen C3, Thate-Waschke IM2, Daniel D3,
Rychlik R3, Bauer TT4
1St. Josef Krankenhaus Haan GmbH, Haan, NRW, Germany, 2Bayer
Vital GmbH, Leverkusen, NRW, Germany, 3Institute of Empirical
Health Economics, Burscheid, NRW, Germany, 4Zentrum für
Pneumologie und Thoraxchirurgie Heckeshorn, Berlin, Germany
OBJECTIVES: In-patient treatment of community-acquired
pneumonia (CAP) is a generally non-invasive therapy with ﬁnan-
cial burden depending on length of hospitalization. In 2004, the
concept of diagnosis-related groups (DRG) was implemented in
Germany. Objective of this study was to analyse the effect of
DRG implementation on length of hospital stay. METHODS:
Open, prospective observational study conducted in German
hospitals before and during DRG-implementation. Between
October 2002 and July 2003 patients with CAP were enrolled
(cohort A). Between January and October 2005 a second inves-
tigation was conducted (cohort B). No intervention in physi-
cians’ treatment decisions was taken. Diagnostic measures, drug
application, non-medical therapy, nursing time and length of
hospital stay were documented by the treating physicians.
RESULTS: In cohort A 319 patients were documented in 9 hos-
pitals, in cohort B 322 patients in 14 hospitals. Cohort A and B
showed no signiﬁcant differences in demographic data, clinical
condition and severity of CAP classiﬁed according to Fine et al.
88.7% (A) and 92.9% (B) of patients were discharged from hos-
pital due to successful treatment. 11.3% (A) and 7.1% (B) of
patients died. Average length of stay was 10.67 (A) and 10.05
days (B) in peripheral ward (p = 0.229), and 0.79 (A) and 0.75
days (B) in ICU (p = 0.847). Overall length of stay was 11.46
(A) and 10.80 days (B) (p = 0.162). CONCLUSIONS: In this
study the effect of DRG-implementation, measured by length of
hospital stay, was marginal. Between 1994 and 2000 a dramatic
reduction of both length of stay and number of hospital beds
were observed because of a number of new laws aiming at cost
reduction. Therefore, the DRG concept for CAP patients has not
yet led to a signiﬁcantly reduction of length of stay in the hos-
pital sector.
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OBJECTIVE: Roﬂumilast is an oral, once-daily PDE 4 inhibitor
under investigation for COPD and asthma therapy. This study
investigated the cost-effectiveness of Roﬂumilast in patients with
severe to very severe COPD, including the ﬁnancial impact on
the UK health care system. METHODS: The analysis was con-
ducted alongside a randomised, placebo-controlled, multina-
tional trial (M2-112) evaluating the efﬁcacy of roﬂumilast in
terms of lung function and the frequency of moderate and severe
(mod/sev) exacerbations in severe and very severe COPD
patients. COPD-related health care use and absence from work
were recorded. Differences in costs were related to differences in
number of mod/sev exacerbations. Trial wide resource use was
